15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Myriad Genetics Inc, 1 rate it Buy or better, 4 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $3.00 to $8.50 (about 2.8x), a sign of real disagreement on valuation. The average target of $4.90 sits 54% above the current $3.17. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.20 next quarter toward $-0.58 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy120%
Hold480%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Myriad Genetics Inc.
As of Sep, 1 of 5 firms rate MYGN a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MYGN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.20
Range $-0.24 – $-0.09 · 8 analysts · -588% YoY
Next period, 8 analysts expect Myriad Genetics Inc to earn $-0.20 a share (range $-0.24 – $-0.09), versus $0.04 a year earlier. Full-year consensus is $-0.76, growing to $-0.58 the year after.
REVENUE · NEXT QUARTER
$195.8M
Range $193.0M – $200.9M · 8 analysts · -7% YoY
Revenue is expected to reach $195.8M (range $193.0M – $200.9M), -6.7% year-over-year. Full-year consensus is $777.7M, rising to $820.7M next year.
Top analysts covering Myriad Genetics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MYGN.
#1
SJ
Sung Ji Nam
Scotiabank · Rank #140
Hold
$6.00+89.0% to target
Overall win rate
46%
+ Follow
#2
David Westenberg
Piper Sandler · Rank #244
Buy
$8.50+167.7% to target
Overall win rate
33%
+ Follow
#3
Matthew Sykes
Goldman Sachs · Rank #274
Buy
$8.00+152.0% to target
Overall win rate
38%
+ Follow
#4
Andrew Cooper
Raymond James · Rank #410
Buy
$8.00+152.0% to target
Overall win rate
24%
+ Follow
#5
LL
Lu Li
UBS
Hold
$6.00+89.0% to target
Coverage
—
+ Follow
MYGN stock forecast FAQ
What is MYGN's average 12-month price target?+
The 5 analysts with a live target average $4.90 for Myriad Genetics Inc over the next 12 months, ranging from a $8.50 high to a $3.00 low.
Is MYGN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 1 are Buy or Strong Buy, 4 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MYGN?+
The Street-high target is $8.50 (Piper Sandler), and the Street-low is $3.00 (Stephens & Co.). The average of all 5 active targets is $4.90.
How many Wall Street analysts cover MYGN?+
5 analysts have an active rating on Myriad Genetics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering MYGN?+
Among analysts who currently cover MYGN, Sung Ji Nam of Scotiabank has the strongest overall Quantellect track record (Rank #140). Their current call is Hold with a $6.00 target.
What is Myriad Genetics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.20 per share (range $-0.24 – $-0.09) across 8 analysts. Full-year EPS is projected at $-0.76, rising to $-0.58 the following year.
How much revenue is Myriad Genetics Inc expected to report next quarter?+
Consensus revenue is $195.8M (range $193.0M – $200.9M). Full-year revenue is projected at $777.7M, growing to $820.7M next year.
Have analysts been upgrading or downgrading MYGN lately?+
As of Sep, 1 of 5 firms rate MYGN a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MYGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Wells Fargo
